RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Wenzhou Kangning Hospital plans a $30 million China IPO to expand its private psychiatric hospital offerings. The company owns three hospitals, all in Zhejiang province, and provides psychiatric services in other hospitals. Two years ago, Kangning, which has a $406 million market capitalization, staged an $88 million IPO on the Hong Kong exchange.
Source: China Biotoday
